Sociodemographic, disease-related characteristics, physical disability, levels of depression, anxiety, fatigue and quality of life of the adult patients with JIA and patients with adult-onset rheumatic diseases
| Variables | Patients with JIA with polyarticular involvement (n=245) | Control group of patients with RA (n=245) | P value | Patients with ERA and JIA (n=110) | Control group of patients with SpA (n=110) | P value |
| Female, n (%) | 183 (74.7) | 183 (74.7) | 1.000 | 41 (38.3) | 42 (38.2) | 1.000 |
| Age at the time of last registered visit, n (%) | ||||||
| 18–39 years old | 156 (62.4) | 156 (62.4) | 0.569 | 76 (69) | 76 (69) | 0.155 |
| 40–59 years old | 76 (31.0) | 76 (31.0) | 0.095 | 27 (24.5) | 27 (24.5) | 0.426 |
| ≥60 years old | 13 (5.3) | 13 (5.3) | 0.561 | 7 (6.4) | 7 (6.4) | 0.147 |
| Disease duration, years (median (Q1; Q3)) | 21.59 (14.79; 31.18) | 12.36 (8.52; 16.67) | <0.001 | 15.76 (9.46; 26.69) | 15.07 (10.36; 19.89) | 0.414 |
| Years of education (median (Q1; Q3)) | 12 (9; 14) | 12 (7; 15) | 0.251 | 12 (9; 15) | 12 (9; 12) | 0.591 |
| Current professional situation, n (%) | ||||||
| Employed | 114 (77) | 143 (81.7) | 0.728 | 55 (73.3) | 76 (82.6) | 0.287 |
| Retired | 8 (5.4) | 7 (4) | 0.621 | 2 (2.7) | 4 (4.3) | 0.568 |
| Retired by disability | 13 (8.8) | 11 (6.3) | 0.598 | 8 (10.7) | 4 (4.3) | 0.082 |
| Unemployed | 13 (8.8) | 14 (8) | 0.432 | 10 (13.3) | 8 (8.7) | 0.537 |
| Active disease, n (%) | 76 (42.5) | 99 (41.5) | 0.787 | 28 (34.1) | 63 (59.4) | <0.001 |
| HAQ score (median (Q1; Q3)) | 0.25 (0; 1) | 0.63 (0.13; 1.13) | < 0.001* | 0 (0; 0.44) | 0.75 (0; 1.5) | 0.025† |
| HADS—depression symptoms, n (%) | 7 (8) | 8 (9.5) | 0.075* | 0 (0) | 9 (14.8) | 0.003† |
| HADS—anxiety symptoms, n (%) | 8 (9.2) | 16 (19) | 0.080* | 4 (9) | 13 (21.3) | 0.002† |
| FACIT-F (median (Q1; Q3)) | 42 (33.5; 47) | 40 (29; 47.5) | 0.041* | 45 (39; 49.5) | 41 (29; 46) | 0.01† |
| EQ5D (median (Q1; Q3)) | 0.62 (0.4; 0.7) | 0.58 (0.45; 0.77) | < 0.001* | 0.69 (0.59; 1) | 0.66 (0.45; 0.7) | 0.155† |
| EQ5D VAS (median (Q1; Q3)) | 79 (50; 90) | 15 (1; 37) | < 0.001* | 75 (50; 90) | 20 (5; 48) | 0.155† |
| SF-36 PC | ||||||
| PF (median (Q1; Q3)) | 75 (50; 90) | 72.22 (45; 95) | < 0.001* | 85 (55; 95) | 80 (50; 90) | 0.690† |
| RP (median (Q1; Q3)) | 81.25 (25; 100) | 75 (25; 100) | < 0.001* | 100 (50; 100) | 75 (25; 100) | 0.621† |
| BP (median (Q1; Q3)) | 62 (41; 84) | 62 (41; 79) | < 0.001* | 62 (42; 84) | 62 (41; 74) | 0.378† |
| GH (median (Q1; Q3)) | 50 (35; 72) | 43.5 (30; 61) | < 0.001* | 51 (37; 67) | 45 (30; 57) | 0.989† |
| SF-36 MC | ||||||
| VT (median (Q1; Q3)) | 56.25 (40; 75) | 50 (47.5; 55) | < 0.001* | 55 (45; 81.25) | 50 (45; 62.5) | 0.523† |
| SF (median (Q1; Q3)) | 87.5 (62.5; 100) | 62.5 (39.5; 100) | < 0.001* | 93.75 (62.5; 100) | 75 (50; 100) | 0.519† |
| RE (median (Q1; Q3)) | 100 (58.33; 100) | 100 (33.33; 100) | < 0.001* | 100 (100; 100) | 91.67 (58.33; 100) | 0.527† |
| MH (median (Q1; Q3)) | 76 (61.4; 88) | 69 (51.7; 86.5) | < 0.001* | 81.4 (64; 90) | 72 (53.5; 82.7) | 0.795† |
Sample size regarding HAQ, HADS, FACIT-F, EQ5D and SF-36 and other variables is not constant due to:
Years of education: JIA with polyarticular involvement n=139; control group of patients with RA n=150; ERA JIA n=70; control group of patients with SpA n=69.
Current professional situation: JIA with polyarticular involvement n=148; control group of patients with RA n=143; ERA JIA n=75; control group of patients with SpA n=76.
Active disease: JIA with polyarticular involvement n=179; control group of patients with RA n=238; ERA JIA n=82; control group of patients with SpA n=110.
HAQ score: JIA with polyarticular involvement n=242; control group of patients with RA n=199; ERA JIA n=88; control group of patients with SpA n=9.
HADS: JIA with polyarticular involvement n=87; control group of patients with RA n=84; ERA JIA n=44; control group of patients with SpA n=61
FACIT-F: JIA with polyarticular involvement n=96; control group of patients with RA n=84; ERA JIA n=48; control group of patients with SpA n=65
EQ5Ds score and VAS: JIA with polyarticular involvement n=77; control group of patients with RA n=108; ERA JIA n=38; control group of patients with SpA n=82.
SF-36: JIA with polyarticular involvement n=99; control group of patients with RA n=160; ERA JIA n=50; control group of patients with SpA n=101.
*After adjustment for disease duration.
†After adjustment for disease activity.
. BP, intensity and discomfort caused by pain; EQ5D, EuroQol-5D; ERA, enthesitis-related arthritis; FACIT-F, Chronic Illness Therapy, Fatigue Scale; GH, general health; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—depression; HAQ, Health Assessment Questionnaire; JIA, juvenile idiopathic arthritis; SF36 MC, mental component of the Short Form 36; MH, mental health; ; SF36 PC, physical component of the Short Form 36; PF, physical function; RA, rheumatoid arthritis ; RE, role limitations due to emotional problems; RP, role limitations due to physical problems; SF, social function; SF36, Medical Outcomes Study 36-item Short Form; SpA, spondyloarthritis; VAS, Visual Analogue Scale; VT, vitality.